🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Inhaled Colistin to Prevent Ventilator-Associated Pneumonia in Patients With Acute Brain Injury

RecruitingNAAges 18 Years - 80 YearsAllSoutheast University, China
NCT06819462 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Ventilator associated pneumonia is the most common manifestation of hospital acquired infections in ICU. The incidence of ventilator-associated pneumonia in patients receiving mechanical ventilation is as high as 20% -71%, which can lead to increased systemic antibiotic use, prolonged mechanical ventilation time and ICU stay, and increased treatment costs. In addition, ventilator-associated pneumonia is also the main cause of hospital infection related deaths in critically ill patients. However, there is a certain buffer time for patients to develop ventilator-associated pneumonia after receiving endotracheal intubation. Previous studies have found that the peak incidence occurs after 7 days of mechanical ventilation, so there is an opportunity for early treatment to prevent infection. Despite the implementation of numerous preventive measures for ventilator-associated pneumonia over th

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Patients aged more than or equal to 18 years and less than 80 years 2. ABI patients admitted to the ICU, including TBI, intracranial haemorrhage, ischaemic stroke, post-cardiac arrest hypoxic-ischaemic encephalopathy or other acute neurological insults 3. Glasgow Coma Scale (GCS) score ≤12 4. Duration of mechanical ventilation more than or equal to 48 hours at enrolment 5. Written informed consent provided by the participant's legally authorised representative. Exclusion Criteria: 1. patients with suspected or confirmed VAP on the day of enrolment 2. Anticipated extubation within the next 24 hours. 3. Duration of mechanical ventilation exceeding 96 hours prior to enrolment. 4. Patients currently receiving or having recently received (within the preceding 24 hours) polymyxin (administered intravenously and/or via nebulization). 5. Known hypersensitivity to polymyxin. 6. Pregnant or breastfeeding women. 7. Myasthenia gravis. 8. Patient with high risk of death within the first 48h after ICU admission. 9. Advanced-stage solid organ malignancy or hematological malignancy.
💊

What it tests

  • Inhaled colistin
  • Inhaled 0.9% sodium chloride
📍

Where

1 site
Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China
Nanjing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy